Global Information
회사소개 | 문의 | 비교리스트

투렛 증후군(중추신경계) : 개발중인 약제(2021년)

Tourette Syndrome (Central Nervous System) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 03월 상품코드 1000821
페이지 정보 영문 74 Pages 배송안내
가격
US $ 2,000 ₩ 2,600,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,201,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,802,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


투렛 증후군(중추신경계) : 개발중인 약제(2021년) Tourette Syndrome (Central Nervous System) - Drugs in Development, 2021
발행일 : 2021년 03월 페이지 정보 : 영문 74 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

투렛 증후군(TS)은 틱으로 불리는 반복적·고정관념적 불수의 운동과 발성을 특징으로 하는 신경장애입니다. 증상에는 눈 깜박임 및 기타 안구 운동, 얼굴찡그림, 어깨를 으쓱하기(shoulder shrugging), 머리 또는 어깨 경련 등이 있습니다. 기타 증상에는 코 만지기, 물건의 냄새 맡기, 팔 퍼덕거리기, 깡충 뛰기 등이 있습니다. 병인으로는 연령을 들 수 있으며, 남성은 여성보다 약 3-4배 더 발병할 가능성이 있습니다. 치료에는 항우울제, 정신 자극약, 행동 요법 등이 있습니다.

투렛 증후군(중추신경계)의 개발중인 약제에 대해 조사했으며, 세계의 치료 상황, 파이프라인 치료법의 리뷰, 개발, 파이프라인 제품의 약제 개요, 주요 기업의 리뷰, 투렛 증후군의 치료에 관한 최신 뉴스 등의 정보를 정리하여 전해드립니다.

목차

  • 서론
  • Global Markets Direct의 리포트 범위
  • 투렛 증후군 - 개요
  • 투렛 증후군 - 치료법의 개발
  • 파이프라인의 개요
  • 기업별 파이프라인
  • 대학/기관별 파이프라인
  • 기업이 개발중인 제품
  • 대학/기관이 개발중인 제품
  • 투렛 증후군 - 치료 평가
  • 타깃별 평가
  • 작용기서별 평가
  • 투여 경로별 평가
  • 분자 유형별 평가
  • 투렛 증후군 - 치료법 개발에 관여하는 기업
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
  • 투렛 증후군 - 약제 개요
  • alpha-dihydrotetrabenazine - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • bevantolol - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • deutetrabenazine - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • dronabinol + palmidrol - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • ecopipam hydrochloride - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • 면역글로불린(인간) - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • NOE-105 - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • sepranolone - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • 중추신경계 장애 및 호르몬 장애에 대해 DRD2에 길항하는 소분자 - 약제 개요
  • 제품 개요
  • 작용기서
  • 연구개발 진척 상황
  • 투렛 증후군 - 휴면 프로젝트
  • 투렛 증후군 - 제조 중지 제품
  • 투렛 증후군 - 제품 개발 마일스톤
  • 주목 뉴스와 프레스 릴리스
  • 2021년 2월 11일 : 새로운 전임상시험에 의해 Sepranolone이 투렛 증후군의 틱을 억제하는 것이 확인
  • 2020년 9월 1일 : EmalexBiosciences의 단계 2b 투렛 증후군 임상시험 등록이 마일스톤에 도달
  • 2020년 3월 24일 : AsarinaPharma에 의한 과거 단계 2b PMDD 데이터 스케줄대로 릴리스
  • 2020년 2월 20일 : Teva의 deutetrabenazine이 소아 투렛 증후군 임상시험에 실패
  • 2019년 8월 28일 : Emalex Biosciences의 투렛 증후군 환자 치료를 위한 에코피팜의 FDA 패스트트랙 지정 취득
  • 2019년 8월 14일 : Emalex Biosciences에 의한 투렛 증후군 소아 환자의 치료에서 에코피팜정의 유효성과 안전성을 평가하기 위한 단계 2 임상시험에 등록된 최초 환자 발표
  • 2019년 8월 6일 : EmalexBiosciences가 Dr.Atul R.Mahableshwarkar를 의약품 개발 담당 상급 부사장으로 임명
  • 2018년 6월 11일 : Therapix Biosciences의 투렛 증후군 연구를 위한 유럽 학회 2018 연차 총회 후원
  • 2018년 4월 9일 : Therapix Biosciences에 의한 Yale University에서의 투렛 증후군 프로그램에 관한 단계 2a 임상시험의 톱라인 결과 발표
  • 2018년 2월 28일 : Nuvelution Pharma에 의한 소아 환자 투렛 증후군의 치료를 목적으로 한 AUSTEDO(R)(듀테트라베나진) 2/3상 임상시험에 대한 환자 등록 개시 발표
  • 2018년 2월 7일 : Therapix Biosciences의 투렛 증후군의 THX-110에 관한 FDA와의 프리 IND 커뮤니케이션 완료 : 임상 개발 계획대로의 진행
  • 2017년 12월 4일 : Therapix Biosciences는 투렛 증후군 프로그램을 위한 Yale University에서의 단계 2a 연구 등록 완료 발표
  • 2017년 10월 11일 : Nippon Chemiphar와 SOM Biotech에 의한 Bevantolol(Calvan)의 새로운 희귀질환의 적응증에 대한 협력
  • 2017년 5월 8일 : TherapixBiosciences와 Hannover Medical School에 의한 투렛 증후군 환자에게서 TXH-TS01의 효과를 평가하기 위한 임상시험 책임 의사가 개시한 임상시험 계약의 체결
  • 2017년 1월 17일 : Psyadon의 소아 투렛 증후군 치료를 위한 에코피팜의 단계 2 임상시험으로부터의 긍정적 결과 발표
  • 부록
  • 조사 방법
  • 조사 범위
  • 2차 조사
  • 1차 조사
  • 전문가 패널 검증
  • 문의
  • 면책사항
KSA 21.05.14

List of Tables

  • Number of Products under Development for Tourette Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Tourette Syndrome - Pipeline by Adeptio Pharmaceuticals Ltd, 2021
  • Tourette Syndrome - Pipeline by Asarina Pharma AB, 2021
  • Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2021
  • Tourette Syndrome - Pipeline by Evero Health Ltd, 2021
  • Tourette Syndrome - Pipeline by Noema Pharma AG, 2021
  • Tourette Syndrome - Pipeline by Octapharma AG, 2021
  • Tourette Syndrome - Pipeline by SOM Biotech SL, 2021
  • Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Tourette Syndrome - Dormant Projects, 2021
  • Tourette Syndrome - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Tourette Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Tourette Syndrome - Overview
  • Tourette Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tourette Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tourette Syndrome - Companies Involved in Therapeutics Development
  • Adeptio Pharmaceuticals Ltd
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • Teva Pharmaceutical Industries Ltd
  • Tourette Syndrome - Drug Profiles
  • alpha-dihydrotetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bevantolol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • deutetrabenazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dronabinol + palmidrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ecopipam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOE-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sepranolone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tourette Syndrome - Dormant Projects
  • Tourette Syndrome - Discontinued Products
  • Tourette Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
  • Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
  • Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
  • Feb 20, 2020: Teva's deutetrabenazine fails in paediatric Tourette syndrome trials
  • Aug 28, 2019: Emalex Biosciences receives FDA Fast Track Designation for Ecopipam for the treatment of patients with Tourette Syndrome
  • Aug 14, 2019: Emalex Biosciences announces first patient enrolled in phase 2b clinical study to evaluate the efficacy and safety of Ecopipam Tablets for the treatment of Pediatric Patients with Tourette Syndrome
  • Aug 06, 2019: Emalex Biosciences appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development
  • Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
  • Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
  • Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO® (deutetrabenazine) for the Treatment of Tourette Syndrome in Pediatric Patients
  • Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
  • Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
  • Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
  • May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
  • Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q